生物医药产业的竞争力，最终体现在集群效应上。 生物医药产业是全球科技革命与产业变革的核心赛道，也是衡量区域经济高质量发展的关键指标。 长期以来，以上海张江、苏州BioBAY为核心的长三角地区，凭借先发的政策布局、密集的科研资源和 完善的产业链配套，在生物医药领域形成先发优势。 面对这一格局，广州黄埔区并未因后发而滞后，而是通过持续优化政策体系、搭建人才集聚平台、聚焦 细分赛道突破，逐步补足产业链短板，以精准培育加生态构建的发展路径，推动区域生物医药产业实现 从跟跑到领跑的"弯道超车"。 随着长期以来的投入，黄埔区也迎来一波生物医药产业发展的弯道超车硕果。南方财经全媒体集团近日 也组织活动，调研广州开发区、广州黄埔区生物医药产业，探寻其中产业发展的奥秘。 而依托核心技术优势，云舟生物的业务也快速从黄埔出发，辐射全球。 截至2024年9月，公司累计为全球客户定制载体数量突破100万，服务覆盖130多个国家和地区的7000余 家机构，其中，在QS前100高校的客户覆盖率达到了90%，全球TOP30药企的客户覆盖率亦超过90%， 产品成果的全球文献引用量逾7000篇，成为全球最大定制化基因载体供应商。 深耕基因递送 ...

Core Viewpoint - The EASY system, developed by Westlake University and the Westlake Coacervate Research Team, is a novel non-viral, non-liposomal nucleic acid delivery platform that has been recognized at the American Society of Gene & Cell Therapy (ASGCT) annual meeting, highlighting its potential in gene delivery applications [1][3][19]. Group 1: Introduction to EASY System - The EASY system is the first mammalian coacervate-based delivery system, designed to efficiently deliver various types of nucleic acids, including plasmid DNA, mRNA, and CRISPR-Cas9 tools [1][5]. - The system is inspired by natural cellular coacervates, which are membrane-less organelles formed through liquid-liquid phase separation, playing crucial roles in various biological processes [6]. Group 2: Mechanism and Advantages - The core of the EASY system is the engineered endogenous protein, ProteanFect™, which self-assembles with nucleic acids to form highly ordered nanoparticle structures [7]. - The delivery process involves the formation of stable nanoparticles, efficient cellular uptake through active endocytosis, intracellular release of nucleic acids, and safe degradation of carrier proteins via natural cellular pathways [8]. - The EASY system offers revolutionary advantages, including: 1. Ultra-high loading capacity, approximately 50 times that of lipid nanoparticles (LNP) [9]. 2. Compatibility with various nucleic acids, enabling the delivery of plasmid DNA, mRNA, siRNA, sgRNA, and Cas9 mRNA [10]. 3. High efficiency and low toxicity, achieving comparable or higher gene delivery efficiency while significantly reducing cell mortality [10]. 4. Broad applicability to various primary cells, including NK cells, B cells, and hematopoietic stem cells [10]. Group 3: Commercialization and Clinical Relevance - The ProteanFect series of kits represents the first commercial product of the EASY system, enabling efficient gene delivery and precise gene editing in various primary and hard-to-transfect cells [13]. - The system has demonstrated high gene editing efficiency in primary T cells, with results showing a range of 67%-88% efficiency for gene marking and over 90% efficiency for gene editing [18]. Group 4: Future Outlook - As gene therapy approaches critical clinical applications, the safety and efficacy of delivery systems are paramount. The EASY system provides a new solution by leveraging the natural biological mechanisms of coacervates [19]. - The international recognition of this technology not only affirms China's scientific innovation but also brings new hope to the global gene therapy field, with expectations for the EASY system to play an increasingly important role in clinical applications [19].